In other words, my short question is this. Can we already see differentially improved profits and capitalisations accruing to a sub-set of corporations (mainly but not only pharma and medical) as most of the economy worsens from the chronic and ever-widening economic and human damage of the COVID-19 pandemic?
see here: https://capitalaspower.com/casp-forum/topic/costly-efficiencies-working-paper-critical-feedback/